Anti-Infective Drugs Advisory Committee

July 28, 2000

Supplemental new Drug Applications (NDA) 19-537/S038, 19-847/S024, 19-857/S027, 19-858/S021, 20-780/S008 for Cipro (ciprofloxacin), Bayer Corporation, Pharmaceutical Division


How we got here, What is Different, Diane Murphy MD   pdf   ppt   htm

Bayer Pharmaceutical Division, Andrew S Verderame ppt htm

Anthrax Clinical Disease and Epidemiology, Martin Hugh-Jones, DVM   pdf   ppt   htm

Human pathology Inhalational Disease, David Walker MD   pdf

Additional slides

Group #1   ppt   htm

Group #2   ppt   htm

Group #3  ppt   htm

Non-Human Primate Model of Inhalational Anthrax, Arthur Friedlander MD   pdf   ppt   htm

FDA Presentation:  FDA's Perspective, Gary K Chikami, MD   pdf

Ciprofloxacin for Prophylaxis of Clinical Disease Due to Inhaled B. anthracis, Andrea Meyerhoff MD MSc DTMH   pdf   ppt   htm